Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors

Journal of Experimental Medicine

Volumn 187, Issue 5, 1998, Pages 693-702

  Ossendorp, Ferry ^a   Mengedé, Erica ^a   Camps, Marcel ^a   Filius, Rian ^a   Melief, Cornelis J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; TUMOR ANTIGEN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; VACCINATION; VIRUS TRANSFORMATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; IMMUNITY, CELLULAR; LEUKEMIA VIRUS, MURINE; LEUKEMIA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VACCINATION; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0032473562     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.187.5.693     Document Type: Article

References (46)

1. Ostrand-Rosenberg, S., A. Thakur, and V. Clements. 1990. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol 144:4068-4071.
2. k negative mouse leukemia cell line K36.16. Immunology. 72:213-218.
3. Chen, P., and H. Aanathaswamy. 1993. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J. Immunol. 151:244-255.
4. - T cell receptor-αβ phenotypes generated in CD8-depleted C57BL/6 mice. J. Immunol. 150:4900-4910.
5. Greenberg, P.D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281-355.
6. Klarnet, J.P., D.E. Kern, K. Okunu, C. Holt, F. Lilly, and P.D. Greenberg. 1989. FBL-reactive CD8 cytotoxic and CD4 helper T cells recognize distinct Friend murine leukemia virus-encoded antigens. J. Exp. Med. 169:457-467.
7. Hu, J., W. Kindsvogel, S. Busby, M.C. Bailey, Y. Shi, and P.D. Greenberg. 1993. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J. Exp. Med. 177:1681-1690.
8. Lilly, F., E.A. Boyse, and L.J. Old. 1964. Genetic basis of susceptibility to viral leukemogenesis. Lancet. ii:1207-1209.
9. Vasmel, W.L.J., M. Zijlstra, T. Radaszkiewicz, C.J.M. Leupers, R.E.Y. De Goede, and C.J.M. Melief. 1988. Major histocompatibility class II regulated immunity to murine leukemia virus protects against early T-but not late B-cell lymphomas. J. Virol. 62:3156-3166.
10. Chesebro, B., B. Miyazawa, and W.J. Britt. 1990. Host genetic control of spontaneous and induced immunity to Friend murine retrovirus infection. Annu. Rev. Immunol. 8: 477-499.
11. Iwashiro, M., T. Kondo, T. Shimizu, H. Yamagishi, K. Takahashi, Y. Matsubayashi, T. Masuda, A. Otaka, N. Fujii, A. Ishimoto, et al. 1993. Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells. J. Virol. 67: 4533-4542.
12. Vasmel, W.L.E., E.J.A.M. Sijts, C.J.M. Leupers, E.A. Matthews, and C.J.M. Melief. 1989. Primary virus-induced lymphomas evade T cell immunity by failure to express viral antigens. J. Exp. Med. 169:1233-1254.
13. Plata, F., P. Langlade-Demoyen, J.P. Abastado, T. Berbar, and P. Kourilsky. 1987. Retrovirus antigens recognized by cytotoxic T lymphocytes activate tumor rejection in vivo. Cell. 48:231-240.
14. b mutant bm13 mice. J. Virol. 68:6038-6046.
15. Chen, W., H. Qin, B. Chesebro, and M.A. Cheever. 1996. Identification of a gag-encoded cytotoxic T lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J. Virol. 70:7773-7782.
16. Kast, W.M., L. Roux, J. Curren, H.J.J. Blom, A.C. Voordouw, R.H. Meloen, D. Kolakofski, and C.J.M. Melief. 1991. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with an unbound peptide. Proc. Natl. Acad. Sci. USA. 88:2283-2287.
17. Schulz, M., R.M. Zinkernagel, and H. Hengartner. 1991. Peptide-induced antiviral protection by cytotoxic T cells. Proc. Natl. Acad. Sci. USA. 88:991-993.
18. Feltkamp, M.C.W., H.L. Smits, M.P.M. Vierboom, R.P. Minnaar, B.M. De Jongh, J.W. Drijfhout, J. Ter Schegget, C.J.M. Melief, and W.M. Kast. 1993. Vaccination with a cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human Papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:2242-2249.
19. Schild, H., M. Norda, K. Deres, K. Falk, O. Rötschke, K.-H. Wiesmüller, G. Jung, and H.-G. Rammensee. 1991. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide. J. Exp. Med. 174:1665-1668.
20. + T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. 54: 4155-4161.
21. Mandelboim, O., E. Vadai, M. Fridkin, A. Katz-Hillel, M. Feldman, G. Berke, and L. Eisenbach. 1995. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat. Med. 1: 1179-1183.
22. Mayordomo, J.I., T. Zorina, W.J. Storkus, L. Zitvogel, C. Celluzzi, L.D. Falo, C.J.M. Melief, S.T. Ildstad, W.M. Kast, A.B. Deleo, and M.T. Lotze. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1: 1297-1302.
23. Sijts, A.J.A.M., F. Ossendorp, E.A.M. Mengedé, P.J. van den Elsen, and C.J.M. Melief. 1994. Immunodominant mink cell focus-inducing murine leukemia virus (MuLV)-encoded CTL epitope, identified by its MHC class I binding motif, explains MuLV-type specificity of MCF-directed cytotoxic T lymphocytes. J. Immunol. 152:106-116.
24. Ljunggren, H.-G., and K. Kärre. 1985. Host resistance directed selectively against H-2 deficient lymphoma variants. J. Exp. Med. 162:1745-1759.
25. Stukart, M.J., A. Vos, and C.J.M. Melief. 1981. Cytotoxic T cell response against lymphoblasts infected with Moloney (Abelson) murine leukemia virus. Methodological aspects and H-2 requirements. Eur. J. Immunol. 11:251-257.
26. Gausepohl, H., M. Kraft, C. Boulin, and R.W. Frank. 1990. Automated multiple peptide synthesis with BOP activation. In Proc. of the 11th American Peptide Symposium. J.E. Rivier and G.R. Marshall, editors. ESCOM, Leiden. 1003-1004.
27. Shimonkevitz, R., S. Colon, J.W. Kappler, P. Marrack, and H.M. Grey. 1984. Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J. Immunol. 133:2067-2074.
28. Bouaboula, M., P. Legoux, B. Pességué, B. Delpech, X. Dumont, M. Piechaczyk, P. Casellas, and D. Shire. 1992. Quantitation of cytokine gene expression using a polymerase chain reaction method involving co-amplification with an internal multi-specific control. J. Biol. Chem. 267:21830-21838.
29. Ossendorp, F., M. Eggers, A. Neisig, T. Ruppert, M. Groettrup, A. Sijts, E. Mengedé, P. Kloetzel, J. Neefjes, U. Koszinowski, and C. Melief. 1996. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity. 5: 115-124.
30. Shimizu, T., H. Uenishi, Y. Teramura, M. Iwashiro, K. Kuribayashi, H. Tamamura, N. Fujii, and H. Yamagishi. 1994. Fine specificity of a virus-encoded helper T-cell epitope expressed on FBL-3 tumor cells. J. Virol. 68:7704-7708.
31. Kondo, T., H. Uenishi, T. Shimizu, T. Hirama, M. Iwashiro, K. Kuribayashi, H. Tamamura, N. Fujii, R. Fujisawa, and H. Yamagishi. 1995. A single retroviral gag precursor signal peptide recognized by FBL-3 tumor-specific cytotoxic T lymphocytes. J. Virol. 69:6735-6741.
32. Alexander, J., J. Sidney, S. Southwood, J. Ruppert, C. Oseroff, A. Maewal, K. Snoke, H.M. Serra, R.T. Kubo, A. Sette, and H. Grey. 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1:751-761.
33. Keene, J.A., and J. Forman. 1982. Helper activity is required for the induction of cytotoxic T lymphocytes. J. Exp. Med. 155:768-782.
34. Gao, X-M., B. Zheng, F.Y. Liew, S. Brett, and J. Tite. 1991. Priming of influenza virus-specific cytotoxic T lymphocytes in vivo by short synthetic peptides. J. Immunol. 147:3168-3173.
35. + T cell help. J. Immunol. 147:4069-4073.
36. + CTL in vivo with peptide vaccine constructs. J. Immunol. 152:529-556.
37. + T cell help. J. Exp. Med. 186:65-70.
38. Hasenkrug, K.J., D.M. Brooks, J. Nishio, and B. Chesebro. 1996. Differing T-cell requirements for recombinant retrovirus vaccines. J. Virol. 70:368-372.
39. Miyazawa, M., R. Fujisawa, C. Ishihara, Y.A. Takei, T. Shimizu, H. Uenishi, H. Yamagishi, and K. Kuribayashi. 1995. Immunization with a single T helper cell epitope abrogates Friend virus-induced early erythroid proliferation and prevents late leukemia development. J. Immunol. 155:748-758.
40. Aichele, P., K. Brduscha-Riem, R.M. Zinkernagel, H. Hengartner, and H. Pircher. 1995. T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med. 182: 261-266.
41. Toes, R.E.M., R.J.J. Blom, R. Offringa, W.M. Kast, and C.J.M. Melief. 1996. Functional deletion of tumor-specific cytotoxic T lymphocytes induced by peptide immunization can lead to the inability to reject tumors. J. Immunol 156: 3911-3918.
42. Toes, R.E.M., R. Offringa, R.J.J. Blom, C.J.M. Melief, and W.M. Kast. 1996. Peptide vaccination can lead to enhanced tumor outgrowth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA. 93:7855-7860.
43. Kearney, E.R., K.A. Pape, D.Y. Loh, and M.K. Jenkins. 1994. Visualization of peptide induced T cell immunity and peripheral tolerance induction in vivo. Immunity. 1:327-339.
44. Matloubian, M., R.J. Concepcion, and R. Ahmed. 1994. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:8056-8063.
45. Von Herrath, M.G., M. Yokoyama, J. Dockter, M.B.A. Oldstone, and J.L. Whitton. 1996. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Virol. 70:1072-1079.
46. + T cells. J. Exp. Med. 184:863-871.